HLA-C and neoplasm: In TCR-CAR, a soluble TCR is fused to the CAR signaling tail, while TCR-like CAR incorporates TCR-like antibodies capable of recognizing the peptide/major histocompatibility complex (MHC) on tumor cell surfaces, combined with CAR signaling to improve target specificity [135,136].